




Mipomersen

Revised: September 19, 2022.

CASRN: 1000120-98-8



Drug Levels and Effects

Summary of Use during Lactation

Mipomersen marketing has been discontinued in the United States. No relevant published information exists with the use of mipomersen during breastfeeding. Because of a concern with disruption of infant lipid metabolism, mipomersen should not be used during breastfeeding.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Cholestyramine, Colesevelam, Colestipol

Substance Identification

Substance Name

Mipomersen

CAS Registry Number

1000120-98-8

Drug Class

Breast Feeding

Lactation

Milk, Human

Anticholesteremic Agents

Antilipemic Agents